PARIS--(BUSINESS WIRE)--Regulatory News: <\/p>\n
NANOBIOTIX (Paris:NANO) (Euronext: NANO ISIN: FR0011341205), a late clinical-stage nanomedicine company pioneering novel approaches for the local treatment of cancer, provides its activities and achievements during 2014 and an overview of anticipated 2015 events including the financial calendar. The Company made major clinical and financial progress, including broadening of indications and strategic plans across Europe, Asia and the US. <\/p>\n
Highlights <\/p>\n
Laurent Levy, CEO of Nanobiotix said: 2014 has been a pivotal year for the Company, with significant progress in clinical development, where we jumped from an early clinical stage to late clinical stage. This has impacted our visibility and exposure from a financial and industrial point of view allowing us to accomplish two capital raises this year. We are now in a position to create value through the expansion of the indications and geographical area of development for the lead product, NBTXR3. As a result, 2015 is expected to be a year of further significant progress with intermediary clinical results, US corporate developments and launch of new indications; all building on the successes of 2014 and preparing for the final steps of CE marking by the end 2016 required before commercial launch. <\/p>\n
Overview <\/p>\n
Expansion of clinical development programme <\/p>\n
The company is developing three different products that can be administered either by direct injection into the tumor (NBTXR3), intravenous injection (NBTX-IV) or topical application to fill tumor cavities just after tumor surgery (NBTX-TOPO). <\/p>\n
NBTXR3 is the first product of the NanoXray portfolio to reach clinical development. The product comprises nanoparticles which can be injected directly into tumor. With the application of radiotherapy, these nanoparticles absorb X-rays which significantly enhances the radiation dose within the cancer cells without increasing the dose to the surrounding healthy tissues. Currently, NBTXR3 is classified as a medical device in Europe and a drug in the United States (US). <\/p>\n
Soft tissue sarcoma (STS): green light to start registration trial <\/p>\n
In June 2014 during ASCO, the Company presented positive Phase I clinical study results for NBTXR3, demonstrating feasibility and safety of intratumoral injection of the product followed by radiotherapy in patients with locally advanced STS. In addition to the feasibility and safety data presented, promising signs of efficacy have been demonstrated. <\/p>\n
<\/p>\n
The rest is here: PARIS--(BUSINESS WIRE)--Regulatory News: NANOBIOTIX (Paris:NANO) (Euronext: NANO ISIN: FR0011341205), a late clinical-stage nanomedicine company pioneering novel approaches for the local treatment of cancer, provides its activities and achievements during 2014 and an overview of anticipated 2015 events including the financial calendar. Continue reading
\nNanobiotix 2014 Review, 2015 Anticipated Milestones and Financial Calendar Nanobiotix Moved up to a New Level: Major ...<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"